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Background:Major Depressive Disorder (MDD) is associated with both proinflammatory
and adaptive immune response abnormalities. Regulatory T lymphocytes (Tregs), a
subtype of CD4+ T cells, are relevant for maintaining immune-inflammatory system
homeostasis and control of inflammation such as the kind potentially induced by the
interactions between the intestinal microbiome and gut mucosa. We investigated the
Treg population and its distribution along their stages of differentiation/activation, as
well as its function in MDD patients without concomitant diseases. We also studied
the potential association between Treg alterations, intestinal barrier damage, and
bacterial translocation.
Methods: 30 MDD patients and 20 healthy controls were studied. The levels of
circulating CD25FoxP3+ Tregs and their distribution on the naïve (TN), effector (TE),
central (TCM), and effector memory(TEM) differentiation/activation stages were analyzed
using polychromatic flow cytometry. Chemokine receptors (CCR) 2, 5, and 6, and the
intracytoplasmic IL-10 expression by the Tregs were also analyzed. The serum IL-10
was measured using Luminex. The serum levels of zonulin and the intestinal fatty
acid-binding protein (I-FABP), both markers of gut barrier function, and the LPS-binding
protein (LBP), a marker of bacterial translocation, were measured using an enzyme-linked
immunosorbent assay.
Results: MDD patients had increased number of circulating Tregs cells with
enhanced number of Tregs at the TN, TE, TCM, and TEM stages. The percentage
of Tregs cells at TN stage was significantly higher in MDD patients. The percentage
of Tregs that expressed CCR2 and CCR6 was increased as well as those
expressing IL-10. MDD patients had significantly increased levels of circulating I-FABP
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and LBP. MDD patients with high LBP levels had a significant reduction in the number of
circulating Tregs compared to normal-LBP MDD patients.
Conclusions: MDD patients showed an expansion of circulating Tregs and their
CD25highFoxP3+ and CD25lowFoxP3+ subsets throughout the different stages of CD4+
T lymphocyte differentiation/activation. Tregs also showed an increased frequency of cells
expressing CCR6 and CCR2. IL-10 Treg production was also enhanced in MDD patients
that concurrently had increased serum IL-10 levels. However, this Treg expansion was
blunted in MDD patients with gut barrier damage and increased bacterial translocation.
Keywords: major depressive disorder, regulatory T lymphocytes (Treg), chemorreceptors, LPS-binding protein, gut
barrier, CD4+ lymphocytes, interleukin 10 (IL10)
INTRODUCTION
Major depressive disorder (MDD) is a disease with high
prevalence. The lifetime risk of depression is 15–18%, meaning
that almost one in five people will experience at least one episode
at some point in their lifetime (1). It is considered to be the third
leading cause of disability worldwide (2). There is increasing
interest in developing a more e!ective MDD treatment in order
to improve the poor response experienced in approximately a
third of the patients (3). Many neurobiological systems have been
implicated in the etiopathogenesis and pathophysiology of MDD
(1). New therapeutic approaches that target MDD pathogenic
mechanisms beyondmonoaminemodulation are needed, in part,
because of the shortcomings of selective serotonin reuptake
inhibitors, serotonin-norepinephrine reuptake inhibitor, and
tricyclic antidepressant treatments.
Experimental and human data have highlighted the
importance of aberrant immune-inflammatory response in
the development of depression (4). The main finding supporting
the abnormal function of the immune system in MDD patients
is the consistency among articles reporting increased circulating
levels of proinflammatory cytokines (5). The risk of depression is
increased in many disorders with an inflammatory component
(6–9). Much of the research has focused on the activation of the
innate immune system (10). However, intriguing new evidence
suggests that the disease profile of MDD patients includes an
immunosuppressive component, especially when involving the
adaptive immune system (11). This pathogenic perspective is
supported by epidemiological data of greater susceptibility to
viral infections, reduced immune responses to vaccines and the
slowed wound healing in MDD patients (12–14). In addition,
depressed individuals with infectious diseases and tumors show
a worse prognosis (15, 16). The understanding of the cellular
mechanisms involved in the pathogenesis of the MDD immune
dysfunction remains partially understood.
Regulatory T lymphocytes (Tregs) are a subtype of CD4+
T cells known to be relevant for maintaining immune system
homeostasis and self-tolerance (17). The Forkhead box P3
(FoxP3) transcription factor and the alpha chain of the IL-
2 receptor (CD25) are the main markers of Tregs (18).
Treg cells are a heterogeneous population based on their
di!erentiation, phenotype, functional activity, and activation
status (19). Depending on the intensity of CD25 expression
two Tregs subsets can be identified, those with high or
low expression (CD25hiFoxP3+ and CD25lowFoxP3+ Tregs,
respectively) with di!erent commitment to Treg cell fate (20, 21).
Two CD25hiFoxP3+ and CD25lowFoxP3+ Tregs subsets may be
identified by the intensity of CD25 expression known as “resting”
and e!ector Treg cells.
Tregs are highly heterogeneous (22). One subdivision is based
on the history of antigen activation that distinguishes naïve (TN)
Tregs from e!ector (TE), central (TCM), and e!ector memory
(TEM) Tregs that can be identified by the expression of the
RO and RA isoforms of the CD45 common leukocyte antigen
family and the CCR7 antigen (23). These Treg subsets have
di!erent distinctive patterns of activation and e!ector functions
(22). In summary, the TN Treg subset exhibits a non-e!ector
function while TCM Tregs can rapidly proliferate and express
e!ector molecules after being stimulated by an antigen and
diminished activation requirements. TEM Tregs produce e!ector
cytokines but have limited proliferative capacity while TE Tregs
are at a final di!erentiation stage and possess high levels of
cytokine production. Tregs can exert their immune suppression
capacity by utilizing di!erent mechanisms. The production of
interleukin (IL) 10 by Tregs is a pivotal mechanism for inhibition
of cells of the innate and adaptive immune responses (24).
Tregs display di!erent homing properties, and their appropriate
compartmentalization is crucial for their in vivo activity. Several
chemokine receptors (CCR) regulate Tregs tissue tra"c including
the migration to inflamed tissues (25). For instance, loss of
CCR6 prevents directing Treg migration to inflamed tissues
whereas CCR5 expression helps in directing Treg migration to
inflamed tissues. Abnormalities in CCR 2, 5, and 6 expression
by Tregs have shown to have pathogenic relevance in di!erent
inflammatory disorders (26).
Quantitative and functional alterations of Tregs have been
implicated in the development of several common autoimmune
and inflammatory diseases such as systemic lupus erithematosus
and rheumatoid arthritis (27). The pathogenic relevance of Tregs
has also been demonstrated in patients with cancer or infectious
diseases. The potential alteration of Tregs in MDD patients has
been investigated but contradictory numbers (increased, normal,
and decreased) of Tregs have been reported (28–32).
Tregs play a key role in the control of harmful inflammation
such as the kind potentially induced by the interactions between
the intestinal microbiome and gut mucosa (33). Damage of
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the intestinal barrier with increased gut permeability and
bacterial translocation has been found in MDD patients (34).
Furthermore, increased levels of the LPS-binding protein (LBP),
a bacterial translocation biomarker, have been associated with a
higher systemic proinflammatory stage and monocyte activation
in MDD patients (35).
Along these lines, we hypothesized that a heterogenous Treg
alteration in MDD patients could explain the contradictory
results previously described. We also investigated a potential
association of gut barrier damage and bacterial translocation
with Treg alterations in MDD patients. We considered it critical
that the phenotypical and functional study of Tregs and gut
barrier permeability had to be performed in MDD patients
without concomitant diseases that could otherwise have potential
interactions with the immune system or with the gut barrier.
Our work focused on the study of a homogeneous population
of 30 patients with refractory MDD and no concurrent diseases
that could be associated with immune system abnormalities.
The patients were not homogenous in terms of pharmacological
treatment. In parallel, we analyzed 20 age- and sex-matched
healthy controls (HCs). We studied the numbers of TN, TE,
TCM, and TEM of Tregs along with their CD25hiFoxP3+ and
CD25lowFoxP3+ subsets. We also analyzed the pattern of CCR
2, 5, and 6 receptor expression and IL-10 production by activated
Tregs, as well as the serum levels of IL-10. In addition, the serum
levels of zonulin and the intestinal fatty acid-binding protein
(I-FABP), both markers of gut barrier function, and the LPS-
binding protein (LBP), a marker of bacterial translocation, were
also measured.
MATERIALS AND METHODS
Patients and Study Protocol
In this study, we included 30 patients with MDD from the
Department of Psychiatry of the Clinica Universidad de Navarra
and from the Hospital Universitario Príncipe de Asturias.
The inclusion criteria included the following: (a) psychiatrist-
confirmed diagnosis of MDD, single or recurrent, according
to the Diagnostic and Statistical Manual of Mental Disorders
criteria, Fifth Edition (DSM-V) (36); (b) a minimum score of
14 points on the 17-item Hamilton Rating Scale for Depression
(HRSD); and (c) age, 18–65 years. Potential subjects were
excluded for the following reasons: (1) acute infection in the last
3 months; (2) chronic bacterial or viral infection; (3) the use of
steroids or immunomodulatory drugs in the last 3 months; (4)
an autoimmune disease; (5) a cardiovascular disease, including
hypertension and ischemic heart disease; (6) a hematopoietic,
lung, hepatic, or renal disorder; (7) an endocrine or metabolic
disease, including diabetes mellitus and hypercholesterolemia,
or a body-mass index (BMI) higher than 30; (8) a history
of malignancy; (9) immunodeficiency and malnutrition; (10)
pregnancy or lactation; and (11) concomitant psychiatric illness,
assessed with theMINI International Neuropsychiatric Interview
(37). The patients with refractory MDD included in the suty
were not homogenous in terms of psychotropic drugs on board.
The patients were studied in parallel with 20 sex-, age-, and
BMI-matched HCs from the same epidemiological area.
This study was approved by the ethics committee of
the University of Navarra and the Hospital Universitario
Príncipe de Asturias. After the study procedures had been fully
explained, the subjects provided written informed consent before
study enrollment.
Blood samples were drawn from all subjects via standard
venipuncture using an established aseptic technique. Samples
were obtained at the time of the evaluation. Serum samples were
also included for analysis. After collection, the samples were
centrifuged, and the serum was isolated, aliquoted, and stored at
!80"C until analysis.
Isolation of Peripheral Blood Mononuclear
Cells
Blood was collected by antecubital puncture from patients
and healthy controls. Peripheral blood mononuclear
cells (PBMC) were obtained from heparinized venous
blood by Ficoll-Hypaque (LymphoprepTM, Axis-Shield,
Oslo, Norway) gradient centrifugation. They were then
resuspended in RPMI 1640 (Biowhittaker Products, Verviers,
Belgium) supplemented with 10% heat-inactivated fetal
calf serum, 25mM Hepes (Biowhittaker Products) and
1% penicillin-streptomycin (Biowhittaker Products). Cell
enumeration was performed by conventional light microscopy
using a Neubauer chamber following trypan blue dead
cell exclusion criteria The viability of fresh PBMC was
checked by both trypan blue (light microscopy) and flow
cytometry exclusion.
In vitro Culture
Stimulated Tregs expression of IL-10 was assessed in vitro intro
intracytoplasmic staining in the presence of brefeldin (38). T cells
were stimulated with 50 ng/ml phorbol-12-myristate-13-acetate
(PMA, Sigma Aldrich Quimica, Spain) plus 1µg/ml ionomycin
(Calbiochem-Novabiochem, La Jolla, CA) for 6 h. The study of
regulatory T lymphocytes was determined in parallel at 4"C in
the absence of exogenous stimuli.
Surface and Intracellular Lymphocyte
Staining
T cells were phenotypically analyzed in PBMC by nine-colors
polychromatic in flow cytometry in a FACSAria cytometer
using FACSDiva software (Becton-Dickinson). For surface
staining, 1 million cells PBMC were incubated in four
FACS tubes with monoclonal antibodies combinations of
fluorescein IsoTioCyanate (FITC)-anti-CCR2/CCR5/CCR6
(Biolegend), peridinin chlorophyll protein (PercP)-anti-CD3
(Biolegend), phycoerythrin-cyanine seven (PE-Cy7)-anti-CD25
(BD), allophycocyanin-alexa-780 (APC-Alexa780)-anti-CCR7
(eBioscience), brilliant violet-405-anti-CD4 (Biolegend), and
brilliant violet-605-anti-CD45RA (Biolegend). The cells were
fixed and permeabilized with Fix and Perm solution (Anti-
Human Foxp3 Set, eBioscience) during 35min, and then, cells
were washed with phosfate saline bu!er (PBS) plus FBS (fetal
bobine serum), and incubated with Permeabilitation Bu!er
and Normal Rat Serum (eBioscience) during 15min. Finally,
the cells were incubated 30min with intracellular monoclonal
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antibodies: phycoerythrin (PE)-anti-IL-10 (Becton-Dickinson)
and allophycocyanin (APC)-anti-FoxP3 (eBioscience).
Quantification of Serum Proteins
To study the concentrations of IL-10 in the serum, the Milliplex
MAP Kit (MERCK, Darmstadt, Germany) was employed using
the protocol recommended by MERCK. The plate was read in a
Luminex MAGPIX with xPONENT software. The concentration
of the cytokine was calculated from the standard curve
using mean fluorescence intensity (MFI) analysis with Analyst
software (MERCK).
To study intestinal barrier damage, the concentration of
I-FABP and zonulin in the serum were measured by enzyme-
linked immunosorbent assay (ELISA). I-FABP was purchased
from Hycult Biotech (Hycult Biotech, PA, USA), and zonulin
was purchased from R&D Systems (R&D Systems, MN, USA).
#e tests were carried out according to the protocols provided
in the kits. #e plate was read in an iMark Microplate Reader
at 450 nm with Microplate Manager So(ware (Termo Fisher
Scientific, MA, USA).
To study bacterial translocation, the concentration of LBP in
the serum was measured by ELISA (Abnova, Taipei, Taiwan). We
performed 1:800 dilutions of the samples from the MDD patients
and HCs. The test was carried out according to the protocol
provided in the kit. The plate was read in an iMark Microplate
Reader at 450 nm with Microplate Manager Software (Thermo
Fisher Scientific).
Statistical Analysis
Analyses were performed using SPSS-19 software (SPSS-IBM,
Armonk, NY). Since most variables did not fulfill the normality
hypothesis, the Mann Whitney U-test for non-parametric data
was used to analyze di!erences between independent groups.
Significance level was set at p < 0.05.
RESULTS
Demographic Patient Characteristics
Table 1 shows the demographic data and clinical characteristics
of the 30 MDD patients and 20 HCs included in the study. No
significant di!erences were found between MDD patients and
HCs with respect to the variables that were studied, except for
employment status. The patient group included 19 females and
11 males, ranging from 27 to 53 years of age. The duration of
their depressive episode before recruitment was 16.12 ± 2.85
weeks. Seventeen patients (56.7%) had su!ered at least one
previous MDD episode. At the time of the study, the mean
value of the HRSD was 15.95 ± 1.25. Furthermore, 10% of the
patients presented psychotic (delusional) symptoms during the
current episode.
All patients received pharmacological treatment at their
doctor’s discretion: 30 (100%) received antidepressant
medications, 28 (93.3%) received anxiolytics or hypnotics,
5 (16.7%) received mood stabilizers, and 10 (33.3%) received
atypical antipsychotics. 28 (93.3%) received combination
pharmacotherapy, consisting of at least 2 di!erent types of
medication in 19 patients (63.3%) and of at least 3 di!erent types
TABLE 1 | Sample characteristics.
MDD HC p-value
Socio-demographic
Age, mean (SD) 43.26 (13.14)40.45 (12.46) 0.45
Sex (% female) 19 (63.3%) 12 (60%) 0.98
Currently employed and active n (%) 13 (59.1%) 18 (90%) <0.01
College degree n (%) 16 (53.3%) 12 (60%) 0.77
Past history
Family history of depression n (%) 17 (56.7%) 8 (40%) 0.38
Family history of other psychiatric disorder n (%) 22 (77.3%) 11 (55.5%) 0.22
Health characteristics and somatic morbilities
BMI, mean (SD) 26.74 (5.41) 25.5 (5.36) 0.51
Smoking n (%) 0.13
Never 12 (40%) 6 (30%)
Occasionally 8 (26.7%) 11 (55%)
Everyday 10 (33.3%) 3 (15%)
Drinking n (%) 0.43
Never 7 (23.3%) 3 (15%)
Occasionally 20 (66.7%) 16 (80%)
Everyday 3 (10%) 1 (5%)
of medication in the other 9 patients (30%). None of the patients
received electroconvulsive therapy (ECT).
MDD Patients Show Increased Number of
Circulating Tregs at the Different Stages of
CD4+ Differentiation
We investigated the circulating counts of Tregs and their
CD25hiFoxP3+ and CD25lowFoxP3+ subsets defined by the
level of CD25 expression in MDD patients and age-, sex-, and
ethnically matched HCs. Figure 1 shows the flow cytometry
gating strategy and histograms of Tregs in a representative case
of MDD patient. We found a significant increase in the number
of circulating Tregs cells in MDD patients with respect to HCs
(p = 0.01) (Figure 2). This Tregs expansion is explained by a
significant increase in the counts of both CD25hiFoxP3+ and
CD25lowFoxP3+ Tregs subsets in MDD patients (p = 0.001).
Furthermore, the percentage of total Tregs (p = 0.005) and of
their CD25hiFoxP3+ (p= 0.003) subset in the circulating CD4+T
population in MDD patients were significantly higher than those
found in HCs.
We also investigated the counts and distribution of
Treg cells and their CD25hiFoxP3+ and CD25lowFoxP3+
subsets at the TN, TCM TEM, and TE stages of CD4+ T
lymphocyte di!erentiation/activation in MDD patients and
HCs (Figure 3). Significant enhanced numbers of total and
both Tregs subsets were found at the four stages of CD4+
T lymphocyte di!erentiation/activation in MDD patients
(p < 0.001). We also found a redistribution of the Treg cells
and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets along
the four stages of activation/maturation. The percentages of
CD25+FoxP3+ Treg cells (p = 0.024) and their CD25hiFoxP3+
(p = 0.01) and CD25lowFoxP3+ subsets (p = 0.01) at TN stage
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FIGURE 1 | Dot plots represent the flow cytometry gating strategy and histograms of the circulating total Tregs and their CD25highFoxP3+ and CD25lowFoxP3+
subsets in a representative case of MDD. The first row dot plots represent the selected gates and percentages to obtain the total Tregs (A), the second those of the
individualized total Tregs and their CD25highFoxP3+ and CD25lowFoxP3+ subsets (B, respectively). The (C) shows dot plots of the selected gates and percentages of
the CCR2 (superior line), CCR5 (medium line), and CCR6 (lower line) expression by total Tregs and their CD25highFoxP3+ and CD25lowFoxP3+ subsets.
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FIGURE 2 | Absolute number and frequency of total circulating Tregs and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets in MDD patients and healthy controls.
Absolute number (cells/µl) (y axis) of CD25+FoxP3+ lymphocytes and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets in MDD patients (gray box plots) and healthy
controls (white box plots) are shown in panel (A). Frequency of the total Tregs and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets in the circulating CD4+ T
lymphocytes in MDD patients (gray box plots) and controls (white box plots) are shown in (B). The top of the rectangle indicates the third quartile, the horizontal line
near the middle of the rectangle indicates the median, and the bottom of the rectangle indicates the first quartile. A vertical line extends from the top of the rectangle to
indicate the maximum value, and another vertical line extends from the bottom of the rectangle to indicate the minimum value. *Significant difference between MDD
and healthy controls for the indicated variable.
were significantly higher in MDD patients than those found
in HCs.
We investigated the potential correlation between the
patients’ HDRS score and their circulating Treg cells and their
CD25hiFoxP3+ and CD25lowFoxP3+ subsets but, we did not
find statistically significant correlations. Neither did we find
statistically significant di!erences between the Tregs counts
among the patients that su!ered their first depressive episode
and those with at least a previous episode. In addition, we did
not find statistically significant di!erences neither with respect to
patients with or without antipsychotic drugs normen andwomen
(Data not shown).
Tregs From MDD Patients Show Increased
CCR6 and CCR2, but Normal CCR5
Expression
We studied the frequency of Tregs cells and of their
CD25hiFoxP3+ and CD25lowFoxP3+ subsets that express the
CCR2, CCR5, and CCR6 chemoreceptors in MDD patients and
HCs (Figure 4). We found that the percentages of the total
Tregs and both subsets that expressed CCR2 and CCR6 were
significantly higher in MDD patients than that in HCs (p< 0.05).
However, there were not significant di!erences in the percentage
of Tregs that express CCR5 between MDD patients and HCs.
MDD Patients Show Increased IL10
Productions by Tregs
We studied the intracellular expression of IL-10 in the Tregs from
MDD patients and HCs after PMA stimulation. We found that
the percentage of the total Tregs that expressed IL-10 in MDD
patients was significantly higher than that in HCs (p = 0.02)
(Figure 5). The increased percentage of Tregs expressing IL-10
in MDD patients was explained by the significantly enhanced
percentages found in the TEM and TE di!erentiation/activation
stages (p= 0.03 and p= 0.02, respectively). Next, in both groups
of subjects, we calculated the potential number of circulating
Tregs that could express IL-10 by multiplying their number
by the percentage of cells that express the cytokine after PMA
stimulation in both groups of subjects (Figure 5). We observed
that the number of circulating Tregs that could express IL-10
was significantly increased in theMDD patients compared to that
found in the HCs (p= 0.02).
We also measured the circulating levels of IL-10 in MDD
patients and HCs (Figure 5). We found that MDD patients had
significantly increased serum concentration of IL-10 compared to
HCs (p= 0.04).
Increased LBP Serum Levels Are
Associated With a Reduction of Tregs in
MDD Patients
We measured the serum concentrations of LBP, zonulin, and
I-FABP in MDD patients and HCs (Figure 6). MDD patients
showed significantly increased levels of LBP and I-FABP
compared to those found in HCs (p = 0.04 and p = 0.01,
respectively). We detected LBP, zonulin and I-FABP in all the
serum from patients.
We found that 11 (high-LBP MDD) out of the 30 MDD
patients had LBP levels higher than the 95th percentile of
those found in HCs (Figure 6). In addition, we found that the
counts of Tregs and of both CD25hiFoxP3+ and CD25lowFoxP3+
Tregs subsets in MDD patients with high-LBP MDD were
significantly lower than those found in normal-LBP patients
(p= 0.003, p= 0.05, p < 0.001, respectively). Interestingly, there
were not significant di!erences in the counts of Tregs and of
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FIGURE 3 | Absolute number and frequency of circulating total Tregs and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets at the TN, TCM TEM, and TE stages of
CD4+ T lymphocyte differentiation/activation in MDD patients and healthy controls. Absolute number (cells/µl) (y axis) of Tregs lymphocytes and their CD25hiFoxP3+
and CD25lowFoxP3+ subsets at the TN, TCM TEM, and TE stages of CD4+ T lymphocyte differentiation/activation in MDD patients (gray box plots) and healthy controls
(white box plots) are shown in (A–C), respectively. Frequency of the total Tregs and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets at the TN, TCM TEM, and TE
stages of differentiation/activation in MDD patients (gray box plots) and controls (white box plots) are shown in (D–F), respectively. The top of the rectangle indicates
the third quartile, the horizontal line near the middle of the rectangle indicates the median, and the bottom of the rectangle indicates the first quartile. A vertical line
extends from the top of the rectangle to indicate the maximum value, and another vertical line extends from the bottom of the rectangle to indicate the minimum value.
*Significant difference between MDD and healthy controls for the indicated variable.
FIGURE 4 | Frequency of CCR2, CCR5 and CCR6 expression by Tregs and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets in MDD patients and healthy controls,
Frequencies of total Tregs and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets (y axis) in MDD patients (gray box plots) and healthy controls (white box plots)
that express the CCR2 (A), CCR5 (B), and CCR6 (C). The top of the rectangle indicates the third quartile, the horizontal line near the middle of the rectangle indicates
the median, and the bottom of the rectangle indicates the first quartile. A vertical line extends from the top of the rectangle to indicate the maximum value, and another
vertical line extends from the bottom of the rectangle to indicate the minimum value. *Significant difference between MDD and healthy controls for the
indicated variable.
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FIGURE 5 | Frequency of IL-10 expression and number of circulating total Tregs and of those at the TN, TCM TEM, and TE stages of differentiation/activation able to
produce this cytokine in MDD patients and healthy controls. Frequencies of total Tregs and of those at the TN, TCM TEM, and TE stages of differentiation/activation
(y axis) in MDD patients (gray box plots) and healthy controls (white box plots) that express IL10 (x axis) after in vitro PMA (50 ng/ml) stimulation for 4 h in total (A).
Absolute number (cells/µl) (y axis) of circulating total Tregs and of those at the TN, TCM TEM, and TE stages of differentiation/activation in MDD patients (gray box plots)
and healthy controls (white box plots) that are able to express the indicated cytokine (x axis) after in vitro PMA stimulation for 4 h (B). Serum concentrations (pg/µl)
(y axis) of IL-10 MDD patients (gray box plots) and healthy controls (white box plots) (C). The top of the rectangle indicates the third quartile, the horizontal line near the
middle of the rectangle indicates the median, and the bottom of the rectangle indicates the first quartile. A vertical line extends from the top of the rectangle to indicate
the maximum value, and another vertical line extends from the bottom of the rectangle to indicate the minimum value. *Significant difference between MDD and
healthy controls for the indicated variable.
both CD25hiFoxP3+ and CD25lowFoxP3+ Tregs subsets between
high-LBP MDD patients and HCs. However, we did not observe
significant di!erences in the expression of IL-10 in the Tregs
between both groups of MDD patients (data not shown).
DISCUSSION
In this paper, we have demonstrated that compared to healthy
controls, MDD patients show a marked expansion of circulating
Tregs and their CD25highFoxP3+ and CD25lowFoxP3+ subsets
through the di!erent TN, TE, TCM, and TEM stages of
CD4+ T lymphocyte activation/di!erentiation. Tregs also
show an increased frequency of cells that express CCR6 and
CCR2. Furthermore, the percentage of CD25+FoxP3+ Tregs
that produce IL-10 is also enhanced in MDD patients that
concurrently have increased enhanced serum IL-10 levels.
However, this Tregs expansion was blunted in MDD patients
with gut barrier damage and increased bacterial translocation.
MDD is associated to a systemic inflammatory response that
has been defined by the established increased concentrations of
circulating proinflammatory cytokines and chemokines found
in these patients (39). In addition, clinical findings and
cellular studies support the knowledge of abnormal function
of the natural and adaptative immune responses (14). The
understanding of cellular mechanisms involved in the MDD
immune system dysfunction remains elusive.
Tregs are a cornerstone of the immune system playing a
critical role in the regulation of the activation and e!ector
activity of cells of the innate and adaptive immune response (40).
Tregs appear to be pivotal in the control and suppression of
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FIGURE 6 | Serum levels of LBP, zonulin and I-FABP in MDD patients and absolute number of circulating Tregs and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets
in high-LBP and normal-LBP MDD patients. Serum concentrations (y axis) of LBP (ng/ml), zonulin (mg/ml) and I-FABP (pg/ml) in MDD patients (gray box plots) and
healthy controls (white box plots) (A). Absolute number of circulating Tregs and their CD25hiFoxP3+ and CD25lowFoxP3+ subsets (y axis) in high-LBP (ascending lined
box plots) and normal-LBP (descending lined box plots) MDD patients subsets and healthy controls (white box plots) (B). The top of the rectangle indicates the third
quartile, the horizontal line near the middle of the rectangle indicates the median, and the bottom of the rectangle indicates the first quartile. A vertical line extends
from the top of the rectangle to indicate the maximum value, and another vertical line extends from the bottom of the rectangle to indicate the minimum value.
*Significant difference between MDD and healthy controls for the indicated variable.
the immune responses against non-self and self-antigens (41).
Our data show a clear increase in the number of Tregs and in
its frequency in the CD4+ T lymphocyte circulating population
in MDD patients. Circulating Tregs represent a versatile
and dynamic cell population that is composed of di!erent
functionally heterogeneous subsets (42). In MDD patients, our
data demonstrate an expansion of both e!ector CD25hiFoxP3+
and resting CD25lowFoxP3+ Tregs subsets compared to those
of the HCs supporting the observed increase in the numbers of
total circulating Tregs. Conflicting results regarding the Tregs
numbers have been previously described in MDD patients
(28–30, 43). Several reasons that are not mutually exclusive may
explain the heterogeneity in the numbers of circulating Tregs
found in MDD patients. First, The di!erences in methodology
for identification of Tregsmay explain the observed discrepancies
between studies.We have applied in this study a current stringent
and precise cytometric strategy of Tregs characterization. Second,
The clinical characteristics of the study samples. We have
analyzed a homogenous population of patient with MDD with
persistent symptomatology for an interval between 10 and
20 weeks. We included as controls a balanced sex, age, and
BMI group of HCs from a similar epidemiological area. We
studied patients with persistent MDD symptoms in spite of
pharmacological treatment because we aimed to discover the
relevance of the impact of the severe disease excluding those with
rapid response to treatment. Furthermore, with this inclusion
criteria, we avoid the reported increase in Tregs numbers during
e!ective antidepressant treatment, whatever antidepressant is
prescribed (44). To prevent potential interference of concomitant
or previous disease and/or treatment with the immune system
function, we applied precise exclusion criteria supporting the
homogeneity of the population and the absence of potential
causes of interference. Third. A new light of explanation of
the heterogeneity in the numbers of circulating Tregs reported
in MDD patients might be inferred from our finding of two
groups of patients, defined by the serum high- and normal-
LBP levels, with normal or increased counts of circulating Tregs,
respectively. Di!erences in the frequency of subjects from both
groups of patients in a cohort may explain discrepancies in
the counts of the Tregs observed between studies. We did
not find di!erences in the Tregs counts between the patients
su!ering their first episode and those with recurrent disease,
which supports linking the expansion of these lymphocytes with
the presence of MDD symptomatology.
The activation of Tregs driven by antigen stimulation
promotes their progression from the naïve stage to the memory
and e!ector stages characterized by di!erentiated functional
and phenotype properties. Thus, in addition to the quantitative
analysis of Tregs in MDD patients, we investigated their
distribution along the di!erent activation/di!erentiation stages.
MDD patients show increased numbers of total Tregs and of
both CD25hiFoxP3+ and CD25lowFoxP3+ Treg subsets at the
di!erent TN, TE, TCM, and TEM stages. These results agree with
previous articles reporting increased percentage of memory Treg
cells in the MDD patients, but the authors did not describe
the other stages of Tregs activation/di!erentiation (30). We
observed a preferential expansion of these Tregs populations at
the TN stage in MDD patients. Although, thymus-derived and
peripherally derived Treg have been identified, our results do
not favor the claimed impairment in Tregs generation in MDD
patients (31, 43). Conversely, this finding suggests that MDD is
associated to a host environment, favoring the cell progression
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to further activation/di!erentiation advanced TCM TEM and TE
stages (45, 46). The observed enhanced expression of IL-10 by
Tregs from MDD patients also support the relevance of an
environment promoting Tregs activation in these patients.
The pattern of CCR expression by Tregs is involved in the
regulation of their homing and inflammatory response patterns.
We have found that Tregs from MDD patients show increased
frequency of cells that express CCR6 and CCR2. It has been
reported than CCR2 and CCR 5 are necessary to ensure e"cient
homing of Treg to inflammatory tissue and migration toward the
antigen site (25). These findings suggest that Tregs from MDD
patients may have an anomalous pattern of tissue migration.
The acquisition of homing receptor phenotypes probably occurs
after the activation of periphery Tregs (23). Thus, the potential
relevance of environment promoting abnormal Tregs activation
in MDDmay be also suggested.
Di!erent mechanisms may be involved in the
pathophysiology of the Treg abnormalities found in MDD
patients. As previously discussed, the observed expansion of
functionally active Tregs in approximately two thirds of the
MDD patients might be favored by a promoting environment.
The consequences of this Treg expansion may be relevant for
the understanding of the pathogenesis of the disease. There is
increasing evidence of the pathophysiological relevance of Treg
heterogeneity and plasticity (46). CD25lowFoxP3+ Tregs can lose
FoxP3 expression and acquire e!ector Th cell function, such as
the Th1 and Th17 phenotypes, under certain conditions, whereas
CD25hiFoxP3+ Tregs are rather stable on mice. Furthermore,
human Treg cells seem to be rather unstable. CD25hiFoxP3+
Treg cells may di!erentiate into Th17 producer cells in the
presence of inflammatory cytokines (47). Former FoxP3+ T
cells are also found to be particularly increased in inflamed
tissues (48, 49). Thus, it is possible to speculate that a Th1 and
Th17 plasticity of the increased numbers of Tregs found in
MDD patients might occur and contribute to a systemic pro-
inflammatory disbalance. Furthermore, the expansion of active
Tregs with suppressor activity on the adaptive immune response
may be involved in the pathogenesis of increased susceptibility
to viral infections, reduced immune responses to vaccines and
the slowed wound healing observed in MDD patients (12–14).
A third of MDD patients have not developed Treg expansion.
In these patients, we found marked gut barrier damage and
increased bacterial translocation. There is evidence that the
microbiota influences the immune system and vice versa.
More specifically, there are close interactions between the gut
microbiota and the Tregs (50). The balance of e!ector lymphoid
cells and Treg cells can have a profound influence on how
the gut mucosa responds to stressors that elicit damage (51).
Furthermore, MDD is associated with an enhanced intestinal
permeability, or “leaky gut,” and increased bacterial translocation
(52, 53). In this subset of MDD patients, we have confirmed
enhanced I-FABP serum levels, a proven peripheral blood
marker of gut barrier function (54). This abnormal intestinal
mucosa barrier favors bacterial, including gram -, translocation.
Circulating LPS promotes the hepatic synthesis of LBP, an acute
phase reactant, and LPS-LBP complexes bind to CD14 on the
monocyte membrane with a subsequent activation of the cell. In
several clinical settings, the long- term (72 h) plasma levels of
LBP induced by transient endotoxemia appear to better reflect
long-term exposure to LPS than does measuring LPS itself (55).
Of interest, LBP is just one of several markers of bacterial
translocation. In agreement with previous reports, our findings
show that as a group, MDD patients have increased LBP serum
levels, with a third also showing a markedly high concentration
of this bacterial translocation marker (56). Interestingly, we
observed a significant reduction in the counts of Tregs and
in both the CD25hiFoxP3+ and CD25lowFoxP3+ Treg subsets
in high-LBP MDD patients in comparison to those found in
normal-LBP MDD patients. The clinical characteristics of the
MDD patients included in this study exclude chronic viral or
bacterial infections, as well as any existence of a concomitant or
recent (at least 3 months prior to the study) bacterial infection.
Thus, these results strengthen the connection between intestinal
barrier dysfunction, bacterial translocation, and the immune-
inflammatory system in MDD patients, with an expansion of
activated monocytes in MDD patients (53). It is possible to
suggest that the reduction of the expansion of Tregs might limit
the gut migration of these cells. This potential reduction of
Tregs of systemic origin could compromise the total number
of intestinal Tregs (57). Treg restriction in the gut mucosa
might favor gut barrier damage and the increased bacterial
translocation found in this previously referenced third of MDD
patients. Although there is no direct evidence of causality, our
results support the relevance of the so-called gut-brain axis,
linking gastrointestinal function and the immune systemwith the
emotional and cognitive brain centers (58, 59).
This work has limitations. It is a cross sectional study
and the course of the disease on natural Tregs need to be
formally tested and replicated in longitudinal studies. The
clinical homogeneity of the MDD patients studied combined
with their very similar HDRS score, undermines the ability
to study the potential association of the Treg expansion with
the severity of the disease. Furthermore, the characteristics and
size of the sample included in this pathophysiological study
also limits the analysis of the potential association of the Tregs
abnormalities with the clinical features of the disease. We have
analyzed a homogenous population of MDD patients presenting
persistent symptomatology for 10–20 weeks. However, all
patients weremedicated, and it might be a cofound. Furthermore,
in this study, we were not able to control for additional
factors that might also be associated with dysregulated cellular
immunity, such as hormonal status, e.g., during menstrual cycle
phases, physical activity, or other lifestyle- or environment-
associated factors.
Taking these results together, two di!erent MDD subsets
can be established according to the analysis of circulating
Tregs. Two thirds of them have an expansion of Tregs whereas
the remaining third has normal Treg numbers, which were
associated with severe gut barrier damage and increased bacterial
translocation. These results support the heterogeneity of the
mechanisms of immune-inflammatory dysfunction in MDD
patients, as well as a need for the individualized biological
study of patients for the development of new immunoregulatory
therapeutic strategies.
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